

TABULA RASA HEALTHCARE, INC.
UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)

	<u>September 30,</u>	
	<u>2016</u>	<u>2015</u>
Cash flows from operating activities:		
Net loss	\$ (219)	\$ (3,949)
Adjustments to reconcile net loss to net cash provided by operating activities:		
Depreciation and amortization	3,415	2,935
Amortization of deferred financing costs and debt discount	1,255	1,575
Payment of imputed interest on debt	(3,893)	(105)
Deferred taxes	(27)	212
Issuance of common stock warrants	—	16
Stock-based compensation	481	471
Change in fair value of warrant liability	(639)	3,477
Change in fair value of acquisition-related contingent consideration	146	(1,348)
Loss on extinguishment of debt	1,396	—
Other noncash items	—	(13)
Changes in operating assets and liabilities, net of effect from acquisitions:		
Accounts receivable, net	(1,729)	(951)
Inventories	(305)	(353)
Rebates receivable	759	308
Prepaid expenses and other current assets	(114)	(191)
Other assets	(171)	79
Acquisition-related contingent consideration	—	(610)
Accounts payable	(191)	322
Accrued expenses and other liabilities	340	912
Other long-term liabilities	1,973	(4)
Net cash provided by operating activities	<u>2,477</u>	<u>2,783</u>
Cash flows from investing activities:		
Purchases of property and equipment	(2,947)	(135)
Software development costs	(1,201)	(669)
Purchases of intangible assets	(29)	—
Change in restricted cash	200	300
Purchase of businesses, net of cash acquired	(1,000)	(2,403)
Net cash used in investing activities	<u>(4,977)</u>	<u>(2,907)</u>
Cash flows from financing activities:		
Payments for debt financing costs	(1,521)	(69)
Repayments of notes payable to related parties	—	(354)
Borrowings on line of credit	6,000	10,000
Repayments of line of credit	—	(6,860)
Payments of acquisition-related consideration	(180)	(1,895)
Repayment of note payable related to acquisition	(14,337)	—
Payments of initial public offering costs	(2,191)	(390)
Payments of contingent consideration	(1,895)	(267)
Proceeds from long-term debt	30,000	—
Repayments of long-term debt	(13,609)	(1,605)
Net cash provided by (used in) financing activities	<u>2,267</u>	<u>(1,440)</u>
Net decrease in cash	(233)	(1,564)
Cash, beginning of period	2,026	4,122
Cash, end of period	<u>\$ 1,793</u>	<u>\$ 2,558</u>
Supplemental disclosure of cash flow information		
Acquisition of equipment under capital leases	<u>\$ 1,470</u>	<u>\$ 353</u>
Additions to property, equipment, and software development purchases included in accounts payable	<u>\$ 238</u>	<u>\$ 15</u>
Deferred offering costs included in accounts payable	<u>\$ 1,006</u>	<u>\$ 1,222</u>
Cash paid for interest	<u>\$ 7,901</u>	<u>\$ 1,807</u>
(Decretion) accretion of redeemable convertible preferred stock to redemption value	<u>\$ (2,439)</u>	<u>\$ 12,058</u>